March 4, 2020 / 12:47 PM / a month ago

BRIEF-AMAG Pharmaceuticals Reports Qtrly Loss Per Share $5.89

March 4 (Reuters) - AMAG Pharmaceuticals Inc:

* AMAG PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* Q4 REVENUE $89.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $88.5 MILLION

* AMAG PHARMACEUTICALS - REAFFIRMS TOTAL REVENUE, OPERATING INCOME, NON-GAAP ADJUSTED EBITDA GUIDANCE FOR 2020

* AMAG PHARMACEUTICALS - AS OF DEC 31, 2019, CO’S CASH & INVESTMENTS TOTALED $171.8 MILLION

* QTRLY LOSS PER SHARE $5.89

* RECORDED TOTAL IMPAIRMENT CHARGES OF $155 MILLION IN Q4 2019

* AMAG PHARMACEUTICALS - IDENTIFIED INDICATORS OF IMPAIRMENT FOR MAKENA SUBCUTANEOUS AUTO-INJECTOR, INTRAROSA AND VYLEESI ASSET GROUPS IN Q4 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below